Skip to content

Penumbra PEN Net Investment in Lease

Net Investment in Lease at other companies

Boston Scientific logo
Boston ScientificBSX

Other financials

Income statement

See full
Revenue$374.8M+15.6%
Gross profit$253.4M+17.4%
Operating income$38.2M-5.2%
Net income$32.6M-16.9%
EPS (diluted)$0.82-18.0%

Balance sheet

See full
Cash & equivalents$241.3M-35.8%
Total debt$216.2M-2.0%
Total equity$1.5B+21.5%
Total assets$1.9B+19.2%

Cash flow

See full
Operating cash flow$87.0M+77.6%
CapEx$13.7M+1.5%
Free cash flow$73.3M+106%

Valuation

See full
Market cap$12.48B+25.1%
Enterprise value$12.45B+26.8%
P/E72.9×-163×
P/S8.6×+0.5×

Profitability

See full
Gross margin67.4%+3.7pp
Operating margin12.9%+9.8pp
Net margin11.8%+8.4pp
FCF margin14.6%+2.5pp

Returns & leverage

See full
Return on equity12.7%+9.2pp
Debt / equity0.1×0.0×
Current ratio-0.3×

Where this comes from

Reported directly by Penumbra in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Penumbra’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Penumbra's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Penumbra's net investment in lease?
Penumbra (PEN) reported net investment in lease of $170.27M in Q1 2026.
How has Penumbra's net investment in lease changed year-over-year?
Penumbra's net investment in lease decreased by 2.9% year-over-year, from $175.33M to $170.27M.
What is the long-term trend for Penumbra's net investment in lease?
Over 5 years (2020 to 2025), Penumbra's net investment in lease has grown at a 33.3% compound annual growth rate (CAGR), from $41.19M to $173.59M.